Funding This work was supported by grants from the National Natural Science Foundation of China (NSFC Numbers 81672800, 81603009, 81673020, 81802632, and 82173830), Natural Science Foundation of Shaanxi (2020JQ-445), and the Key Research and Development Program of Shaanxi Province (2021SF-207, 2021SF-223, and 2022ZDLSF05-19)
Compared with FeSAN, the redox peak intensity of TMB in the presence of pFeSAN was much stronger, indicating more available active sites of pFeSAN for more efficient TMB oxidation
Scientific References TripleHormone-Receptor Agonist Retatrutide for Obesity (Phase 2 Trial)
For a full overview of how the Therapeutic Goods Administration treats laboratory peptide and reconstitution supplies in Australia, see our peptide legality and TGA compliance guide
PMC 2408600